Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?

Valberg M, Grotmol T, Tretli S, Veierød MB, Moger TA, Devesa SS, Aalen OO.

Eur J Epidemiol. 2016 Jul 18. [Epub ahead of print]

PMID:
27431530
2.

Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.

Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS, Gann PH, Kibel AS, Vickers AJ, Mucci LA.

J Clin Oncol. 2016 Aug 10;34(23):2705-11. doi: 10.1200/JCO.2016.66.7527. Epub 2016 Jun 13.

PMID:
27298404
3.

Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group.

Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, Bray F, Cook MB, Devesa SS.

Int J Cancer. 2016 Mar 15;138(6):1388-400. doi: 10.1002/ijc.29894. Epub 2015 Nov 27.

4.

Meta-Analysis of Long-Chain Omega-3 Polyunsaturated Fatty Acids (LCω-3PUFA) and Prostate Cancer.

Alexander DD, Bassett JK, Weed DL, Barrett EC, Watson H, Harris W.

Nutr Cancer. 2015;67(4):543-54. doi: 10.1080/01635581.2015.1015745. Epub 2015 Mar 31. Review.

5.

Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.

Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I.

J Natl Cancer Inst Monogr. 2013;2013(46):117-23. doi: 10.1093/jncimonographs/lgt010.

6.

The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis.

Chua ME, Sio MC, Sorongon MC, Morales ML Jr.

Can Urol Assoc J. 2013 May-Jun;7(5-6):E333-43. doi: 10.5489/cuaj.1056.

7.

Lycopene, Tomato Products, and Prostate Cancer Incidence: A Review and Reassessment in the PSA Screening Era.

Wei MY, Giovannucci EL.

J Oncol. 2012;2012:271063. doi: 10.1155/2012/271063. Epub 2012 May 28.

8.

Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey.

Swan J, Breen N, Graubard BI, McNeel TS, Blackman D, Tangka FK, Ballard-Barbash R.

Cancer. 2010 Oct 15;116(20):4872-81. doi: 10.1002/cncr.25215.

9.

Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.

Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.

J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.

10.

Awareness and use of the prostate-specific antigen test among African-American men.

Ross LE, Uhler RJ, Williams KN.

J Natl Med Assoc. 2005 Jul;97(7):963-71.

11.

Prostate cancer incidence and mortality rates and trends in the United States and Canada.

McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD.

Public Health Rep. 2004 Mar-Apr;119(2):174-86.

12.

Toward a better understanding of the comparatively high prostate cancer incidence rates in Utah.

Merrill RM, Hilton SC, Wiggins CL, Sturgeon JD.

BMC Cancer. 2003 Apr 29;3:14.

Supplemental Content

Support Center